Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Total Liabilities (2016 - 2026)

Corcept Therapeutics (CORT) has disclosed Total Liabilities for 15 consecutive years, with $176.9 million as the latest value for Q1 2026.

  • For Q1 2026, Total Liabilities rose 8.41% year-over-year to $176.9 million; the TTM value through Mar 2026 reached $176.9 million, up 8.41%, while the annual FY2025 figure was $188.8 million, 17.32% up from the prior year.
  • Total Liabilities hit $176.9 million in Q1 2026 for Corcept Therapeutics, down from $188.8 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $191.7 million in Q3 2025 and bottomed at $54.0 million in Q2 2022.
  • Average Total Liabilities over 5 years is $124.3 million, with a median of $118.3 million recorded in 2024.
  • Year-over-year, Total Liabilities skyrocketed 120.97% in 2023 and then grew 8.41% in 2026.
  • Corcept Therapeutics' Total Liabilities stood at $81.6 million in 2022, then skyrocketed by 40.72% to $114.8 million in 2023, then skyrocketed by 40.2% to $161.0 million in 2024, then grew by 17.32% to $188.8 million in 2025, then dropped by 6.33% to $176.9 million in 2026.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $176.9 million, $188.8 million, and $191.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.